Novartis AGNVSNYSE
Loading
SG&A Expenses Over TimeStable
Percentile Rank36
3Y CAGR+3.0%
5Y CAGR-1.3%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+3.0%/yr
vs -2.9%/yr prior
5Y CAGR
-1.3%/yr
Recent acceleration
Acceleration
+5.9pp
Accelerating
Percentile
P36
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
3 yr
Consecutive growthStable
PeriodValueYoY Change
2025$13.31B+5.9%
2024$12.57B+0.4%
2023$12.52B+2.7%
2022$12.19B-4.9%
2021$12.83B-9.6%
2020$14.20B-1.2%
2019$14.37B+4.8%
2018$13.72B+10.0%
2017$12.46B-12.2%
2016$14.19B-